Management of hyperglycemia associated with pasireotide in patients with Cushing’s disease or acromegaly. Recommendations from a panel of experts
PDF (Español (España))

Keywords

Pituitary ACTH Hypersecretion
Acromegaly
Hyperglycemia
Pasireotide

How to Cite

Pinzón-Tovar, A. ., Abreu Lomba, A. ., Arenas, H. M., Gomez Giraldo, C. M. ., Pantoja Guerrero, D. ., Valenzuela, A. ., García, A. F. ., & Buitrago Gómez, N. (2022). Management of hyperglycemia associated with pasireotide in patients with Cushing’s disease or acromegaly. Recommendations from a panel of experts. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 9(3). https://doi.org/10.53853/encr.9.3.738

Abstract

Context: Pasireotide has demonstrated efficacy in the treatment of cushings disease and acromegaly; however, it is common for patients treated with pasireotide to have hyperglycaemia.

Objective: To provide for Colombia a management guide for hyperglycemia secondary to pasireotide administration in patients with acromegaly or Cushing's disease.

Methods: The Experts panel performed a thorough review of the available evidence to answer clinical questions made by experienced endocrinologists around the country. During the panel, the experts used the updated evidence to formulate recommendations.

Results: The panel made sixteen recommendations for treating hyperglycemia in patients with Cushing's disease and seven for acromegaly receiving pasireotide. Guidance is both evidence and experience-based.

Conclusions: Although pasireotide is an effective therapy for inoperable pituitary tumors, its secondary hyperglycemia and diabetes are complications to be considered. There is little evidence to support specific recommendations to treat primary or secondary hyperglycemia in these patients, here the recommendations were based on expert opinion and are the first published for Colombia.

https://doi.org/10.53853/encr.9.3.738
PDF (Español (España))

References

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med. 2012;366(10):914–24.

Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing ’ s disease?: the state of the art. Endocrine. 2014;47:9–20.

Fleseriu M, Cuevas-Ramos D. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther. 2016;227.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.

Castellanos-Bueno R, Abreu-Lomba A, Buitrago-Gómez N, Patiño-Arboleda M, Pantoja-Guerrero D, Valenzuela-Rincón A, et al. Clinical and epidemiological characteristics, morbidity and treatment based on the registry of acromegalic patients in Colombia: RAPACO. Growth Horm IGF Res [Internet]. 2021 Oct;60–61(101425):101425. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1096637421000484

Ceballos-delgado Y, Carvajal R, Buitrago-gómez N, Delgado A, Rivera A, Osorio V, et al. Efectividad de la terapia con análogos de somatostatina sobre el control de pacientes con acromegalia no curados con tratamiento quirúrgico en un centro de alta complejidad. Rev Colomb Endocrinol Diabetes Metab [Internet]. 2021;8(1):1–12. Available from: https://doi.org/10.53853/encr.8.1.661

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.

Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999 Jan;48(1):77–85.

Ceccato F, Scaroni C, Boscaro M. Clinical use of pasireotide for Cushing ’ s disease in adults. Ther Clin risk mangement. 2015;11:425–34.

Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19(5):536–43.

Reznik Y, Bertherat J, Borson-chazot F, Brue T, Chanson P, Cortet-rudelli C. Management of hyperglycaemia in Cushing ’ s disease?: Experts ’ proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41.

Colao A, Block C De, Sonia M, Sudhesh G, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing ’ s disease treated with pasireotide?: medical expert recommendations. Pituitary. 2014;17:180–6.

Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study 1. J Clin Endocrinol Metab. 2001 Jan;86(1):117–23.

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994 Apr;40(4):479–84.

García JMM. Hipercortisolismo de origen suprarrenal?: síndrome de Cushing. Medicine (Baltimore). 2008;10(15):967–75.

Bertagna X, Guignat L, Groussin L. Cushing ’ s disease. Best Pract Res Clin Endocrinol Metab. 2009;23:607–23.

Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: Clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–26.

Ferrau F. Metabolic comorbidities in Cushing ’ s syndrome. Eur J Endocrinol. 2015;173:M133–57.

Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003 Jun;88(6):2527–33.

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004 Dec;61(6):768–77.

Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri E-A, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002 Nov;87(11):4872–8.

Petersenn S. How to manage pasireotide, when using as medical treatment for Cushing’s disease. Endocrine. 2015;50(3):526–8.

Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome?: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506.

van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009 Feb;39(2):81–93.

Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D, et al. An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers. Am J Ther. 2014;21(3):164–73.

Ministerio de Salud y Protección Social de Colombia. pospopuli. 2016.

Breitschaft A, Hu K, Hermosillo Res??ndiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458–65.

Scacchi M, Cavagnini F. Acromegaly. Pituitary. 2006;9(4):297-303.

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Dec;99(11):3933–51.

Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, et al. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014 Nov;99(11):4003–14.

Ntali G, Karavitaki N. Recent advances in the management of acromegaly [version 1; referees: 2 approved] F1000Research 2015, 4(F1000 Faculty Rev):1426 (doi: 10.12688/f1000research.7043.1).

Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8.

Cordido F, García Arnés JA, Marazuela Aspiroz M, Torres Vela E. Guía práctica de diagnóstico y tratamiento de la acromegalia. Endocrinol y Nutr. 2013;60(8):457.e1-457.e15.

Chih Hao C-K. Guías para el diagnóstico y tratamiento de acromegalia, prolactinomas y enfermedad de Cushing. Acta Med Costarric. 2004;46:25–36.

Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: An Italian survey. Eur J Endocrinol. 2012;167(2):189–98.

Colao A, Bronstein MD, Freda P, Gu F, Shen C-C, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014 Mar;99(3):791–9.

Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152–77.

Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014 Feb;17(1):81–9.

Dreval a V, Trigolosova I V, Misnikova I V, Kovalyova Y a, Tishenina RS, Barsukov I a, et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect. 2014;3(2):93–8.

Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011 Sep;14(3):231–5.

Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Brazilian J Med Biol Res = Rev Bras Pesqui me?dicas e biolo?gicas / Soc Bras Biofi?sica . [et al]. 2001 Nov;34(11):1429–33.

Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011 Jun;164(6):877–84.

Møller N, Schmitz O, Jøorgensen J, Astrup J, Bak J, Christensen S, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy: Vol 74, No 5. J Clin Endocrinol Metab. 1992;74(5):1012–9.

Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000 May;52(5):549–55.

Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009 May;94(5):1500–8.

Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. J Endocrinol Invest. 2015;39(2):235–55.

Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, et al. Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest. 2012;35(2):154–9.

Samson SL. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. 2016;76(13):1235–43.

Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary [Internet]. 2021;24(6):887–903. Available from: https://doi.org/10.1007/s11102-021-01161-4

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Dimensions


PlumX


Downloads

Download data is not yet available.